Coping with diabetes requires frequent and even today mostly invasive blood glucose-based monitoring.
Introduction
In view of its dynamic behaviour in the presence of multiples stress, the human skin is widely used to test cellular and molecular responses to specific treatments. Since the skin is one of main organs that are predisposed towards developing damage in diabetic patients, so that between 1/3 and nearly all diabetic patients experience cutaneous complications (1) (2) (3) (4) , the developing of a non-invasive device for sensing glucose by means of the skin has become a focus of interest for scientists and commercial companies worldwide (5) (6) (7) (8) . In fact, the currently most widely used devices require skin penetration as far as the interstitial fluid, and are thereby invasive, although a new generation of devices based on the measurement of various metabolites in sweat such as sodium, lactate, potassium and glucose has been proposed recently (9) (10) (11) (12) . One major drawback with such devices, however, is the amount of sweat required, resulting in secondary effects such as skin irritation. In view of all the devices available on the market and the unknown biological behaviour of skin in response to high glucose, we propose a new paradigm that operates by converting the skin cells to serve as biosensors for monitoring blood glucose.
Keratinocytes are the main cell type (≈90 %) constituting the epidermis (13, 14) , and with respect to their key roles in wound healing (15), they have been extensively studied, notably in cases of diabetes (16) (17) (18) . Reports have demonstrated that impaired keratinocyte function can result in delayed wound healing, and that multiple physiological processes in keratinocytes, such as proliferation (19) , migration (20), apoptosis (21) and differentiation (22), may be affected by a hyperglycaemic condition. Moreover, the skin barrier dysfunction (23,24) and increased inflammation (25-27) brought about by a hyperglycaemic environment will prevent the keratinocytes from healing, probably leading to continuously infected severe skin lesions (28, 29) . In view of the literature, keratinocytes could be used as indicators of the status of normal and diabetic skin.
We set out here to investigate whether blood glucose concentration could be monitored by means of keratinocytes and whether a specific signalling pathway is activated by this sensing. Our results show that Trisk 95 expression is increased in the skin and its primary keratinocytes following an increase in blood glucose concentration. In turn, upregulation of Trisk 95 is associated with an increase in the intracellular calcium level, which then triggers a particular modification in the morphology of the mitochondrial network. Our data demonstrate that a specific signalling pathway is activated in the skin 4 and its primary cells in response to a high glucose concentration. These results lead us to propose that keratinocytes could serve as promising biosensors for developing a new generation of blood glucose monitoring devices, especially in diabetic patients.
Results

Skin glucose levels are rapidly influenced by glucose concentrations in the blood
Little is known about the responses of epidermal cells to increased blood glucose concentrations or whether a particular signalling network is activated in these cells. To test this hypothesis, we first injected glucose into healthy and type I diabetic mice, the latter having been prepared as previously described (30) . Briefly, C57BL/6 mice were divided into two groups: (healthy) controls, which were injected intraperitoneally with citrate buffer (pH 4.5), and type I diabetic mice, which received one single dose of 150 mg/kg streptozotocin (STZ). Blood glucose was monitored every 48 hours and the mice were considered diabetic when its level was ≥ 15 mmol/l (data not shown). The first step was to select a suitable end-point at which the blood glucose level in the healthy mice reaches that found in the diabetic mice (≥ 15 mmol/l), as this can be used for collecting the skin samples. For this purpose, we performed a glucose tolerance test (GTT) on the healthy mice. After fasting for 12 hours, the mice were divided into two groups: a control group in which PBS was injected intraperitoneally, and a treatment group that received 2gr/kg D-glucose. Serum was collected from both groups (15 animals/group) at time-points 0, 5, 15, 30 and 45 min and blood glucose levels were monitored. The results showed a significant increase in blood glucose at 5 min post-injection in the glucose-injected mice (15.20 mmol/l±1.36) ( Fig. 1a , full circle) as compared with the placebo-treated mice (6.27 mmol/l±0.31) ( Fig. 1a , empty circles). The glucose concentration remained at this level up to the 45 min time-point and then started to drop (Fig. 1a ).
Blood insulin measurements showed a significant increase upon the injection of glucose in the healthy mice (1.8 ng/ml±0.76 versus 0.83 ng/ml±0.076 in the placebo-injected mice), whereas the blood insulin concentration in the type I diabetic mice did not differ between those receiving a placebo or a glucose injection (0.25 ng/ml±0.038; and 0.20 ng/ml ±0.026 respectively) ( Fig. 1b) . Although the blood insulin concentration in both the placebo and glucose-injected type I diabetic mice was significantly lower than in their healthy counterparts (Fig. 1b) , a certain background level of insulin was detected in both, suggesting that the STZ treatment did not destroy all the -cells. 6 To determine whether the skin glucose level changes upon an increase in blood glucose concentration, skin and blood samples were taken 45 min after a glucose injection, whereupon the level was seen to be significantly increased in the healthy mice (3.95±0.38 mmol/mg protein in glucose-injected mice versus 1.14±0.58mmol/mg protein in the placebo-injected mice) ( Fig. 1c ). Interestingly, a significantly high amount of glucose was detected in the skin of both the placebo and glucose-injected type I diabetic mice (27.35±3.5; and 25.67±4.3 mmol/mg protein; respectively) ( Fig. 1c ). To find the mechanism by which blood glucose is taken up by the skin, we examined the expression of glucose transporter-1 (Glut-1) at the mRNA and protein levels. Our data demonstrated a 26-fold increase in Glut-1 mRNA in the healthy mice after the glucose injection ( Fig. 1d ), while the Glut-1 protein level was upregulated ( Fig. 1e ).
Examination of Glut-1 expression in the diabetic mice indicated that glucose injection affected neither its mRNA expression nor its protein expression ( Fig. 1d, e ). On the other hand, the Glut-1 mRNA expression level in the placebo-injected type I diabetic mice was 3.4-fold higher than in the placeboinjected healthy ones ( Supplementary Fig. 1a ). This may explain why the glucose level is significantly higher in the skin of diabetic mice than in that of healthy mice. Taken together, these results suggest that a modification in blood glucose concentration will regulate the skin glucose level in the same direction.
Trisk 95 is a novel biomarker for detecting glucose in the skin
To determine whether a specific pathway is activated in the skin upon an increase in blood glucose concentration, we performed label-free differential proteomic analyses of the skin biopsies taken from the placebo and glucose-injected healthy and type I diabetic mice. The results showed that Triadin isoform-1 (Trisk 95) was the only protein among all those screened (n=1824) that significantly increased in both the healthy and type I diabetic groups after glucose injection ( Fig. 2a ). To investigate further the effect of blood glucose concentration on Triadin expression, Trisk 95 mRNA levels were measured in the skin of the different groups of mice.
Consistent with the proteomic data, the results showed 3.45 to 4-fold increases in Trisk 95 mRNA in both the healthy and type I diabetic mice receiving an intraperitoneal injection of glucose ( Fig. 2b ). Since the blood insulin concentration in type I diabetic mice does not change after a glucose injection of, we 7 concluded that the upregulation of Trisk 95 in the skin mediated by an increase in blood glucose takes place via an insulin-independent pathway.
To further verify the effect of glucose on the Trisk level, we examined Trisk 95 expression in primary mouse keratinocytes cultured in the presence of low (5 mM) and high (25 mM) D-glucose concentrations.
In this experiment, primary keratinocytes isolated from healthy mice were cultured in a low-glucose medium for 10 days. The medium was then replaced with a fresh medium containing either a low (5 mM) or a high (25 mM) glucose level. Forty-five minutes later cell and medium samples were collected for further analysis. Measurement of the glucose uptake indicated a significant increase in glucose consumption when the cells had been incubated for 45 min in the presence of a high glucose concentration (2.43±0.1mmol/ug protein versus 0.43±0.07mmol/ug protein) ( Fig. 2c ), while Trisk 95 mRNA and protein expression levels had likewise increased 2.3 and 1.6-fold, respectively ( Fig. 2d , e, f).
Consistently with this, immunostaining of keratinocytes pointed to a significant increase in the expression of Trisk 95 (red) when cells were cultured in the presence of 25 mM D-glucose ( Fig. 2g and Supplementary Fig. 2a, b ).
To further examine whether the glucose concentration affected the transcriptional expression of Trisk, we used a luciferase reporter plasmid in which the 882 bp region upstream of the ATG translation initiation codon of human TRDN had been cloned upstream of the luciferase. The results showed a significant increase in luciferase expression upon treatment of the cells with 25 mM D-glucose ( Fig. 2h ), indicating that the extracellular glucose concentration affects Triadin expression at the transcriptional level.
An increased blood glucose concentration will trigger intracellular calcium level modifications
Given that Trisk 95 is a well-known actor in calcium release from the endoplasmic reticulum (ER) in skeletal and heart muscles (31-34), we then wondered whether the Trisk 95 overexpression mediated by a high glucose concentration might affect the calcium level in the ER store. To answer this question, the basal level of intracellular calcium was imaged live using Fluo-4 AM 45 min after culturing primary mouse keratinocytes with either a low or a high-glucose medium. 8 To evaluate the release of calcium from ER, thapsigargin (an inhibitor of sacro/endoplasmic reticulum Ca2+ ATPase (SERCA) pump function) was added to block the pumping of calcium back into the ER.
A significant increase in the maximum amplitude (background-subtracted F1/F0, where F0 is the minimum level of fluorescence before adding thapsigargin) was observed in the cells incubated with 25 mM D-glucose compared with the controls (0.32±0.037 versus 0.2±0.02) ( Fig. 3a) . We then measured the speed with which half of the maximum fluorescence amplitude was reached, and the results showed a significant difference between these two conditions, the speed being significantly slower in the cells incubated with high glucose (76.82±5.28 second) than in the controls (62.16±3.59 second) ( Fig. 3b ), suggesting that the release of calcium from the ER was higher under these conditions. Two representative To test the in vivo effect of the blood glucose concentration on the calcium level in the skin, the GTT test was performed on the healthy mice. The relative basal calcium level in freshly isolated keratinocytes was then measured by flow cytometry using Fluo-4 AM. The results indicate that keratinocytes isolated from the glucose-injected mice had significantly higher basal calcium concentrations than cells taken from their control counterparts (4.33±0.26 versus 2.87±0.29 in the glucose and placebo-injected mice, respectively) ( Fig. 3c ).
Primary keratinocytes exhibit alteration in mitochondrial network morphology due to the Trisk
upregulation
To test the hypothesis that mitochondria act to buffer intracellular calcium levels through the action of the mitochondrial calcium uniporter complex (34,35), thereby affecting mitochondrial metabolism and the morphology of the mitochondrial network (36,37), we first examined the effect of the extracellular glucose concentration on mitochondrial morphology using electron microscopy (EM). The results showed that the majority of the mitochondria were subjected to a modification in their morphology when cells were incubated with 25 mM D-glucose ( Fig. 4a ). For quantification purposes, we classified the mitochondria into two groups: 1a normal group that can take various shapes (elongated or round) with arranged cristae and an electron-dense matrix (yellow dotted circles) ( Fig. 4a ), and 2an abnormal group 9 that are swollen, enlarged and round in shape, the disarrangement of their cristae accompanied by a partially or totally electron-lucent matrix (red dotted circles) ( Fig. 4a ).
Quantitative analyses indicated that while the majority of the mitochondria in the cells incubated with low glucose belonged to the normal group, the majority of those in the cells incubated with high glucose exhibited an abnormal shape ( Fig. 4a, b ). Since mitochondria always behave as a network (38,39), we then assessed the effect of a high glucose concentration on the morphology of the mitochondrial network in keratinocyte mitochondria staining with the MitoTracker probe. While the majority of the control keratinocytes demonstrated an interconnected network located mostly around the nucleus, the majority of the cells incubated with high glucose exhibited a fragmented mitochondrial network that was dispersed in the cytoplasm ( Fig. 4c, d ).
To examine whether mitochondria are also affected under our in vivo conditions, skin biopsies were collected from the four groups of mice and visualized under EM. A similar mitochondrial phenotype was observed in the basal keratinocytes of both the healthy and type I diabetic groups upon receiving an injection of glucose. Indeed, while the majority of the mitochondria in the placebo-injected healthy group belonged into our normal mitochondrial class (yellow dotted circles) ( Fig. 4e , f), the majority of those in both the glucose-injected healthy and type I diabetic groups were swollen, enlarged and round in shape with disarrangement of their cristae (red dotted circles) accompanied by a partially or totally electronlucent matrix ( Fig. 4e, f) .
Significantly, the number of mitochondria belonging to the normal group was lower in the placeboinjected type I diabetic mice than in the placebo-injected healthy mice and that of the abnormal group higher ( Fig. 4f ). This could have been due to the high glucose level found in the skin of the type I diabetic mice even in the absence of glucose injection (see Fig. 1c ).
Trisk 95 knockout abolishes the increase in intracellular calcium mediated by a high glucose concentration and rescues the mitochondrial phenotype in the skin and its primary keratinocytes
To investigate the functional relation between Trisk 95 and intracellular calcium during the skin's response to high blood glucose, skin biopsies were collected from the Trisk 95 KO mice 45 min after the injection of glucose or a placebo. To evaluate the basal calcium level, keratinocytes isolated from both groups were loaded with Fluo-4 AM. The results did not show any significant differences in basal calcium concentration between the placebo and glucose-injected Trisk 95 KO mice (2.74±0.62 versus 3.83±0.58, p=0.27) ( Fig. 5a ), indicating that Trisk 95 expression is necessary for high blood glucosemediated modification to the skin calcium homeostasis.
In order to assess the role of Trisk 95 in the transitional modification of the mitochondrial phenotype, keratinocytes isolated from Trisk 95 KO mice and cultivated in the presence of low or high glucose were examined by EM. Interestingly, the majority of the mitochondria in the Trisk 95 -/keratinocytes incubated with high glucose exhibited an elongated shape accompanied by arranged cristae and an electron-dense matrix (Fig. 5b , c), a phenotype that has been classified as normal. These results indicate that Trisk 95 expression plays an important role in keratinocyte responses to the extracellular glucose level. To examine this hypothesis further, skin mitochondrial phenotype comparisons were made between the placebo and glucose-injected Trisk 95 -/mice, whereupon the results showed that the majority of the mitochondria in the basal keratinocytes were normal in both groups ( Fig. 5d , e), indicating that Trisk 95 downregulation blocks the mitochondrial phenotype modification mediated by a high blood glucose concentration in.
To further examine the role of calcium in mitochondrial phenotype modification when monitoring high extracellular glucose concentrations, keratinocytes isolated from healthy mice were first incubated with BAPTA, a well-known calcium chelator, for 45 min and then subjected to low or high glucose conditions for 45 min. Histological examination of the mitochondrial phenotype indicated that treatment with DMSO (in which BAPTA was dissolved) did not affect the influence of extracellular glucose on the mitochondrial phenotype ( Fig. 5f , see also Fig. 4b ). The addition of BAPTA, however, significantly reduced the number of abnormal mitochondria in the cells subjected to high glucose ( Fig. 5g ). Taken 11 together, our results indicate that the mitochondrial phenotype is triggered by calcium changes and can be rescued by adding BAPTA.
In order to analyse the molecular mechanism by which cytoplasmic calcium fluctuation could trigger mitochondrial phenotype alternation in the skin and its primary cells, we examined the expression of MCU and MICU1 (two well-known mitochondrial calcium uniporters) in the skin, and found that, upon subjection to high glucose injection, MCU and MICU1 expression at the mRNA level were significantly increased in both healthy (3 and 2.8-fold increases, respectively) and type I diabetic mice (3.8 and 4-fold increases) compared with their control counterparts ( Fig. 5h , i). Interestingly, when looking at MCU and MICU-1 expression levels in the Trisk 95 KO mice, we found that only MCU was significantly upregulated in the glucose-injected mice relative to the placebo-injected ones (a 1.16-fold increase) but not MICU1 (Fig. 6j ). These findings suggest firstly that MCU and MCU1 are required together for activation of the mitochondrial calcium uniporter complex in keratinocytes, allowing calcium uptake, and secondly that the main function of Trisk 95 in keratinocyte responses to high extracellular glucose is to orchestrate that activation. 12 
Discussion
We have shown here that the skin and its primary keratinocytes rapidly sense any increase in blood glucose concentration and trigger a response network.
Our results showed that upon an increase in blood glucose concentration the skin cells in both healthy and type I diabetic mice take up more glucose, suggesting that this takes place through an insulinindependent pathway. When looking for the mechanism underlying this increased uptake of glucose by keratinocytes we found that Glut-1 mRNA expression was significantly increased in the mice receiving D-glucose compared with the controls, and that Glut-1 mRNA expression was significantly higher in the type I diabetic mice than in the healthy mice, which may explain the higher skin glucose level.
A previous study has shown that keratinocytes were regulating their glucose uptake under hyperglycaemia by reducing the expression of the glucose transporter (Glut-1) (18). In that experiment, the keratinocytes were incubated for 5 days in a medium with either a low or a high glucose concentration, whereas in our protocol the period of incubation was 45 min. Our results indicate that keratinocytes are sensitive to the extracellular glucose concentration and that acute and chronic glucose sensing could lead to different responses. It is now important to understand how glucose is detected by keratinocytes and to know what the outcomes of increased glucose uptake by keratinocytes are.
Triadin is a key player in the functioning of the heart and skeletal muscles in that it regulates the excitation-contraction (EC) coupling process (32,40-42). Moreover, it modulates intracellular calcium haemostasis via its interaction with various proteins such as Junctin (43), RYR (44,45) and CSQ (46). Indeed, it has been shown that Triadin regulates calcium release from the sarcoplasmic reticulum (SR) by binding directly to the RYR receptor in a specific domain (47). This interaction regulates RYR activity, leading to modification in the level of intracellular calcium in the myoblast cell line (48) and in the skeletal muscles cells (49). Our results show that a high extracellular glucose concentration induces Trisk 95 upregulation at the transcriptional level by regulating its promotor ( Fig. 2h ).
To test whether RYR and CSQ expression is modified under our conditions, we looked at their expression in our mice models. The results showed a significant increase in the RYR-1 mRNA level in both glucoseinjected healthy and type I diabetic mice relative to their counterparts ( Supplementary Fig. 4a, b ). 13 Regarding CSQ-2 mRNA, its expression level was significantly increased in the glucose-injected type I diabetic mice ( Supplementary Fig. 4a, b ). Similar results were obtained from primary keratinocytes after 45 min of high glucose incubation ( Supplementary Fig. 4c ). Based on our results, we propose the following model for describing skin responses to fluctuations in blood glucose concentration ( Fig. 6 ). In healthy individuals (blood glucose level ~ 5 mmol/l), Trisk 95 does not bind RYR-1 or CSQ-2 and a constant calcium leak from ER into the cytosol is maintained via the RYR-1 channels. Under those conditions the cytoplasmic calcium is involved in physiological processes in the mitochondria (Fig. 6a ).
Under type I diabetic conditions, however, in which blood glucose levels are high (≥ 15 mmol/l), Trisk 95 is upregulated at both levels (mRNA and protein). Binding of the skin Trisk 95/CSQ-2 complex to the RYR-1 channels leads to their closure and subsequently to increased ER calcium stores. This increase in ER calcium eventually triggers modifications in the mitochondrial network and consequently in its optimal functioning ( Fig. 6b ).
Consistently with a critical role for Trisk 95 in orchestrating skin responses to an increase in the blood glucose concentration, increased calcium levels and modifications to the mitochondrial phenotype and network were absent in the glucose-injected Trisk 95 KO mice (Fig. 5a ), and similarly no changes were observed when examining RYR-1 and CSQ-2 mRNA levels in Trisk 95 KO skin in response to a highglucose injection ( Supplementary Fig. 4d ).
Our findings in these respects are in disagreement with previous data claiming a significant reduction in calcium release in Trisk 95 KO myotubes and muscles (32,42). However, our data obtained from the overexpression of Triadin in keratinocytes confirm previous claims of higher resting SR calcium in heart muscle and myotubes cells (40,50). In the light of our data and those of others, we speculate that Trisk 95 may be a key player in regulating the ER calcium store via regulation of the RYR channels.
It is worth mentioning that Inositol 1,4,5-trisphosphate receptor (IP3R) is playing role in regulating the calcium release from ER in keratinocytes (51-53). In addition, it has been reported that Triadin regulates IP3 receptors in rat skeletal myoblasts (54), further investigations to show whether possible interaction between Trisk 95 and IP3R might take place in keratinocytes. 14 It is known that a high concentration of calcium induces differentiation markers such as loricrin, profilaggrin and involucrin in keratinocytes (55-57), and it has also been shown that keratinocytes located in different layers of the epidermis express different RYR receptors (58). The effects of the calcium level and of RYR expression upon the upregulation of Triadin under hyperglycaemia may therefore explain the poor wound healing observed in type I diabetes.
Given that calcium signalling is a key regulator of mitochondrial behaviour (59), we hypothesize that an increase in intracellular and ER calcium may affect mitochondrial function. Our data obtained in vivo and in vitro indicate that mitochondria present a specific phenotype after high glucose in the skin of both healthy and type I diabetic mice. The mitochondrial phenotype might be attributable to calcium uptake resulting in mitochondrial damage (60). The mitochondrial calcium uniporter complex is responsible for calcium uptake across the inner membrane (34,35,61,62), and in agreement with this, our data showed that the expression of MCU and MICU1 at the mRNA level was significantly upregulated after high glucose in both healthy and diabetic mice ( Fig. 5h , i). seen to occur during the first 6h, followed by a second modification starting from 48h and lasting until 7 days in the presence of high glucose (70). In view of the literature and our present results, we speculate that increased calcium may induce changes in ROS production in our model, so that further investigations should be considered. 15 Overall, our study highlights the rapid, dynamic physiological behaviour occurring in the skin and its primary keratinocytes in response to blood glucose concentration. The data demonstrate for the first time that high blood glucose for 45 min induces the activation of a number of players that are cross-talking, leading to the activation of signalling cascades. Trisk 95 is shown to be an essential mediator in the interaction between these cascades and proposes that the ensuing calcium can be used as an indicator of the blood glucose level in the skin. This work represents the first step of our registered patent (No. PCT FI2016/050917, https://encrypted.google.com/patents/ WO2017109292A1?cl=no), and suggests further studies for developing the device that is able to detect the biological changes in the cells and convert them to a value.
Relationships between calcium and mitochondrial morphology changes have been reported in astrocytes
Materials and Methods
Cell culture and glucose treatment
Primary keratinocytes were isolated from the skin of 6-8-week-old mice as previously described (Supplementary ref. 1 ). Briefly, mice (C57/BL6) were sacrificed (by cervical dislocation) and the hair shaved from their backs. The skin was then sterilized by immersion in a beaker of 10% betadine for 2 min, in a beaker of 70% ethanol for 1 min and then in sterile Dulbecco's phosphate (PBS) for 1 min. The skin samples were treated with trypsin for 2h at 33°C to separate the epidermis from the dermis.
Keratinocytes were cultured in F12 (21765-037) -DMEM (41965-062), medium, both from Thermo Fisher, supplemented with hydrocortisone (0.5 µg/ml), epidermal growth factor (EGF) and insulin (5 µg/ml), all from Sigma. The medium was changed three times a week. When the cultures reached 70-80% confluence the keratinocytes were incubated with two concentrations of D-glucose (G7021-Sigma) (5 mM + 20 mM mannitol (for osmolality)) or 25 mM for 45 min and then used for the various experiments.
The type I diabetic mouse model
Type I diabetes was induced after one single intraperitoneal (IP) injection of streptozotocin (STZ), as previously described (30). One week before the experiment, all the mice were housed in individual cages.
On the day of the experiment, they fasted for 4h and were then divided into two groups: controls and type I diabetic mice. The control mice were injected IP with Na citrate buffer (pH 4.5), while the type I diabetic mice were injected with STZ (150 mg/kg) diluted in Na citrate buffer to a total volume of 100µl.
The mice were diagnosed as diabetic when their blood glucose level was ≥ 15 mmol/l.
Insulin measurement
To determine the insulin concentration in the serum, blood samples were collected from the facial vein of the mice 45 min after the D-glucose injection. Serum was obtained after centrifugation at 3500 rpm for 10 minutes at 4° C and insulin was measured using the Insulin Rodent (Mouse/Rat) Chemiluminescence ELISA kit (ALPCO) according to the manufacturer's instructions
Glucose tolerance test
For adaptation purposes, the mice were housed in individual cages for one week. Prior to the experiment the healthy and type I diabetic mice fasted overnight (12h) and each group was then divided into two parts, yielding four groups in all: healthy and type I diabetic groups that were injected intraperitoneally (IP) with PBS, and healthy and type I diabetic groups that were injected IP with D-glucose (2g/kg). Blood glucose levels were monitored at 0, 5, 15, 30-and 45-min post-injection. After 45 min, all the mice were killed and skin samples were collected for the various experiments (RT-qPCR, western blotting and EM).
All the animal procedures were performed in accordance with the European Convention (ETS 123), EU Directive 86/609/EEC and the Finnish national legislation, as approved by the local ethical committee.
RNA extraction from skin samples and primary keratinocytes
Total RNA was extracted from the skin using Trizol (Invitrogen, 15596-026) and subsequently the RNeasy Mini Kit (Quiagen). The tissues were cut into small pieces, incubated with Trizol for 5 min at 4°C and homogenized using TissuLyser TM (Qiagen) for 5 min at 50 Hz. Skin lysates were centrifuged for 15 min at 13000 rpm at 4°C, after which chloroform was added to the supernatant and the samples incubated for 5 min at RT followed by centrifugation for 18 min at 13000 rpm at 4°C. The rest of the extraction steps were performed using the RNeasy Mini Kit according to the manufacturer's instructions.
The RNeasy Mini Kit was also used to purify the RNA from the primary keratinocytes. The quality of the RNA from both the skin and the cells was assessed using nanodrop.
To analyse the mRNA expression level of Trisk 95, 2 μg of RNA was reverse transcribed to cDNA using the SuperScript™ VILO™ cDNA Synthesis Kit (ThermoFisher, 11754050) or the First Strand cDNA synthesis kit (Roche Applied Science). Quantitative real-time PCR was carried out for Glut-1, Trisk 95, RYR-1, CSQ-2, MCU, MICU1, 18S and GAPDH using primers from a TaqMan gene expression assay and the SYBER Green method. The primer sequences used are listed in Table 1 . The reactions were cycled 40 times after initial polymerase activation (50°C, 2 minutes) and initial denaturation (95°C, 20 minutes) using the following parameters: denaturation at 95°C for 1 second, and annealing and extension 18 at 60°C for 20 seconds. The relative expression of target genes was normalized to 18S or GAPDH expression and the ΔΔCT method was applied followed by a two-tailed Student's t-test.
Luciferase reporter assay
The Triadin promoter region containing a 882 bp (chr6:123636957+123637838) DNA fragment was 
Measurement of glucose uptake and intracellular glucose consumption
To evaluate glucose uptake or its intracellular concentration, we used the YSI 2950 Biochemistry Analyzer (YSI Life Sciences), which employs immobilized enzyme to catalyse the corresponding chemical reactions in order to measure the concentration of a specific metabolite. Briefly, to measure glucose uptake, keratinocytes were incubated in triplicate for 45 min in a 24-well plate in 1 ml of DMEM complete medium supplemented with glucose (5 mM or 25 mM). The concentration of glucose in the collected medium was evaluated by the YSI analyser using corresponding fresh medium as a reference.
To measure intracellular glucose concentrations, skin samples taken from the various groups of mice were immersed in a hypotonic buffer (2.5 mM Tris/HCl, pH 7.5 and 2.5 mM MgCl2) on ice for 15 min, homogenized and then sonicated for 15 s. The concentrations of glucose in the skin lysates were then evaluated. The data were expressed as mmol·μg−1 of protein. To assess calcium levels after GTT, keratinocytes were isolated from skin biopsies collected at 45 min and stained Fluo-4 AM was added to the medium and incubated in the dark for 30 min. After two washes with PBS, the cells were analysed by flow cytometry. Data from ten thousand individual cells were collected for each sample.
Intracellular calcium imaging and measurement
Immunostaining of cells
To examine the expression of Trisk 95 and its localization in the primary keratinocytes, cells were cultured in dishes with a glass bottom for 45 min after treatment with two concentrations of glucose.
They were then fixed in 4% paraformaldehyde (PFA) for 10 min at RT and incubated with blocking solution (10% BSA, TBST (Tris buffer saline-Tween) 0.1%) for 30 min. This was followed by a further incubation with the primary antibody anti-Trisk 95, as previously described (Supplementary ref. 2 ), diluted in the blocking solution for 1h at RT and then with DAPI, and with a secondary antibody for 30 min. Fluorescence was detected using a confocal microscope (Zeiss LSM 780, Carl Zeiss, Germany). 21 Skin biopsies were collected from the four groups (three mice per group) after the GTT assay, and cultured cells were mounted on coverslips and fixed in 1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffer, pH 7.4. The remaining steps were followed as previously described (Supplementary ref. 4 ). Sections from the skin samples and cells were examined using a Tecnai Spirit G2 transmission electron microscope. Images were captured with a Veleta CCD camera and Item software (Olympus Soft Imaging Solutions GMBH, Munster, Germany).
Transmission electron microscopy (TEM)
Statistical analysis
GraphPad Prism software, version 7, was used for the statistical analyses. The one-way or two-way ANOVA test or the two-tailed Student t-test were employed and *P-values less than 0.05 were Cells were incubated for 30 min in the presence of Fluo-4 AM and intracellular calcium basal levels were measured for 50 seconds, after which thapsigargin was added to the medium. Time lapse recording was used to follow the increase in the fluorescence signal until the maximum amplitude was reached. The data showed a significant increase in the amount of cytosolic calcium in the cells incubated with high glucose relative to the controls (n=41). b Speed required to reach the half maximum of the fluorescence signal. The keratinocytes incubated with high glucose were slower to reach their peak than were the controls. c High extracellular glucose increased calcium uptake. The GTT test was performed using healthy mice. Keratinocytes were isolated from the skin and stained using Fluo-4 for 30 min. The relative intensity of staining was then measured by flow cytometry. The results are presented as means ± SEM (n=3 animals and 10000 cells/mouse). The two-tailed Student's t-test was used for statistical analysis in a (* P <0.01), b (* P <0.02) and c (* P <0.019). expression in the skin. mRNA expression levels of MCU and MICU1 in the skin of healthy (h), type I diabetic (i) and Trisk 95 KO (j) mice was examined using qRT-PCR. The results are shown as the averages after normalization to the controls ± SEM (n=6/group). The two-tailed Student's t-test was used in a (ns. not significant P =0.27) and in e * P <0.01, ** P <0.009, *** P <0.0006. One-way ANOVA (multiple comparison) was used in d (* P <0.01, ****P <0.0001), f (**** P <0.0001, *** P <0.0001, ** P <0.0014), and g (** P <0.003, * P <0.041) and the two-tailed Student's t-test was used in h (*** P <0.0002, * P <0.012), i (* P <0.042 and * P <0.025) and j (* P <0.035). Table 1 Primer sequences for quantitative real-time PCR
